Latest News and Press Releases

BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new...

Dublin, April 23, 2025 (GLOBE NEWSWIRE) -- The "PSMA - Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This report provides information on approved...

SHANGHAI, April 01, 2025 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Research Outlook 2029" report has been added to ResearchAndMarkets.com's offering. Bispecific antibody...

Dublin, March 12, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030" report has been added to ...

Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report has been added to ResearchAndMarkets.com's offering. The development of...

Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Technologies Market 2024" report has been added to ResearchAndMarkets.com's offering.The blood brain barrier technologies market...

SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...